Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PLD approaches its October 15 earnings release with a stock that has shed 6.5% over the past month to $129.49, even as the broader lending market shows almost no conviction from short sellers. Short interest is just 1.7% of the free float, down 11.7% over the past month, and borrow availability is extraordinarily loose at over 5,300%. Borrowing costs are a negligible 0.39%. Options positioning is slightly less defensive than usual: the put/call ratio of 0.92 is modestly below its 20-day average of 0.96, sitting roughly half a standard deviation lower, well within normal range. The setup is one where price has weakened but there is no meaningful short-side pressure building to explain or amplify it.
The gap between where the stock trades and where analysts think it belongs is the more striking tension. The consensus price target is $159.75, implying roughly 23% upside from current levels, and the direction of recent analyst moves has been constructive. After a wave of target increases following the Q2 print in July, with Barclays lifting to $156, Truist to $162, and Mizuho to $159, the most recent activity has been mixed but not alarming: RBC Capital upgraded to Outperform in August, while Wells Fargo trimmed its target fractionally to $166 in September, maintaining Overweight. The bull case rests on Prologis's 1.3 billion square foot global portfolio, roughly $60 billion of third-party AUM, and a management team projecting around 6% annual FFO growth, with U.S. vacancy improving to 7.2% and full-year absorption guidance raised to 220 million square feet. Bears push back on the rent trajectory: rates fell roughly 5% in 2025 after an 8% drop in 2024, and with industrial supply still running elevated and global trade risks unresolved, the argument is that pricing power has not yet recovered enough to justify the premium valuation. The stock trades at a PE of 38.8 and EV/EBITDA of 22, both of which have eased over the past month as the share price has retreated.
The only insider activity worth flagging is a 50,000-share sale by Chairman Hamid Moghadam in July at $149.91, worth $7.5 million, executed under a pre-arranged 10b5-1 plan. Planned sales carry far less signal than discretionary ones, and the CFO's smaller 10b5-1 sale in June followed the same pattern. Net insider activity over 90 days is negative at roughly 50,000 shares sold, but the mechanistic nature of those transactions mutes the read-across. On the ownership side, BlackRock raised its stake to 10% in a June amendment, up from 9.3%, while various Vanguard entities collectively hold above 13%. No activist holder appears on the 13D register. ORTEX also puts a 65% probability on a MSCI World share-count increase for Prologis, linked to a potential acquisition of SEGRO, with any tracker trade not expected until late April 2027.
The October 15 print will test whether the rent recovery narrative management has been building is translating into numbers that can close even part of the gap between a stock trading near $130 and a Street consensus anchored above $159.
See the live data behind this article on ORTEX.
Open PLD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
